Trials / Recruiting
RecruitingNCT07121777
Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
An Exploratory Clinical Study of Anti-CD19/BCMA CAR Gene Vector Injection (LCAR1901) for the Treatment of Refractory Autoimmune Diseases
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Anhui Provincial Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of Refractory Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with an Anti- CD19/BCMA CAR gene vector injection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis | A single intravenous infusion of anti-CD19/BCMA CAR gene vector injection(dose-escalating infusion of 1.0-4.0 x10\^6 TU/kg） |
Timeline
- Start date
- 2025-08-25
- Primary completion
- 2029-08-31
- Completion
- 2029-08-31
- First posted
- 2025-08-13
- Last updated
- 2025-08-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07121777. Inclusion in this directory is not an endorsement.